Clinical trials: Severe Chronic Plaque Psoriasis
Chronic Plaque-type Psoriasis
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT00941031
- Testing
- AIN457, AIN457A
- Where
- 62 sites in United States, France and 5 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00645905
- Testing
- adalimumab
- Volunteers
- 148 people
- Sponsor
- Abbott
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
- Trial name
- NCT03230292
- Testing
- Bimekizumab
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00645814
- Testing
- adalimumab
- Volunteers
- 148 people
- Sponsor
- Abbott
Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00646191
- Testing
- adalimumab
- Volunteers
- 137 people
- Sponsor
- Abbott
Chronic Plaque-type Psoriasis
A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with moderate-to-severe psoriasis.
- Trial name
- INDUS-2 (NCT04207801)
- Testing
- AUR101
- Where
- 9 sites in India
- Volunteers
- 90 people
- Sponsor
- Aurigene Discovery Technologies Limited
Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.
- Trial name
- NCT03051217
- Testing
- Certolizumab Pegol
- Where
- 33 sites in Japan
- Volunteers
- 127 people
- Sponsor
- UCB Biopharma S.P.R.L.
Plaque Psoriasis
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01483924
- Testing
- Apo805K1
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- ApoPharma
Psoriasis
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00504270
- Testing
- RG3421 120mg, RG3421 20mg
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Hoffmann-La Roche
Psoriasis
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- CHAMPION (NCT00235820)
- Testing
- adalimumab, MTX
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Abbott
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The primary objectives of the study are: To evaluate the safety and tolerability of three dose levels of MT-1303 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01987843
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 52 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 142 people
- Sponsor
- Tanabe Pharma Corporation
Moderate to Severe Chronic Plaque Psoriasis
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate…
- Trial name
- STELLAR-2 (NCT05335356)
- Testing
- Stelara, Bmab1200
- Where
- United States
- Volunteers
- 384 people
- Sponsor
- Biocon Biologics UK Ltd
Moderate to Severe Chronic Plaque-type Psoriasis
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03504852
- Testing
- secukinumab 150 mg
- Where
- 67 sites in United States, Canada and 5 more
- Volunteers
- 331 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic…
- Trial name
- reSURFACE 1 (NCT01722331)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg
- Volunteers
- 772 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque Psoriasis
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for…
- Trial name
- NCT05388916
- Testing
- Cosentyx
- Where
- 7 sites in China
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of Bimekizumab compared with…
- Trial name
- BE ABLE 1 (NCT02905006)
- Testing
- Bimekizumab
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 250 people
- Sponsor
- UCB Biopharma S.P.R.L.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE BRIGHT (NCT03598790)
- Testing
- Bimekizumab
- Where
- 189 sites in United States, Australia and 11 more
- Volunteers
- 1,353 people
- Sponsor
- UCB Biopharma SRL